Fraser McKay
Optometrist · Louisville, KYNPI 1447668058
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 195 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,202 and has fallen 53.3% since, to $562 in 2025. Among optometrist clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 195 payments — averaging $29.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alcon$715
- Amgen$622
- Sun Pharmaceutical Industries Inc.$517
- Novartis$435
- Aerie Pharmaceuticals, Inc.$373
- plus $2K from 17 others
What the payments were for
- Food & beverage$5,54198%
- Education$1292%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 46 | $1,223 |
| Alcon | 15 | $715 |
| Amgen(2 entities) | 21 | $622 |
| Sun Pharmaceutical Industries Inc. | 18 | $517 |
| Novartis | 26 | $435 |
| Aerie Pharmaceuticals, Inc. | 6 | $373 |
| Tarsus Pharmaceuticals, Inc. | 4 | $233 |
| Mallinckrodt Hospital Products Inc. | 6 | $226 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $207 |
| Kala Pharmaceuticals, Inc. | 4 | $158 |
| Eyevance Pharmaceuticals LLC | 2 | $150 |
| Oyster Point Pharma, Inc. | 6 | $150 |
| Regeneron Healthcare Solutions, Inc. | 5 | $131 |
| Bausch & Lomb Americas Inc. | 6 | $111 |
| Dompe US, Inc. | 4 | $103 |
| Harrow Eye, LLC | 5 | $94 |
| Astellas Pharma US Inc | 4 | $81 |
| Sight Sciences, Inc. | 3 | $45 |
| Rxsight Inc | 2 | $26 |
| Biotissue Holdings Inc. | 2 | $24 |
| Apellis Pharmaceuticals, Inc. | 1 | $16 |
| Ivantis, Inc | 1 | $16 |
| Spark Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$368
- Rhopressa$367
- Rocklatan$347
- XEN GLAUCOMA TREATMENT SYSTEM$245
- CEQUA$208
- Tobradex ST$139
- LUMIGAN$134
- SIMBRINZA$127
- ReSTOR$125
- AcrySof IQ PanOptix$125
- EYSUVIS$116
- Clareon$109
How this compares
$5,669 in reported general payments places this provider in the 90th percentile of 712 optometrist providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 21 | $748,780 |
| RestasisCyclosporine | 133 | $103,762 |
| LumiganBimatoprost | 179 | $65,677 |
| XiidraLifitegrast | 25 | $32,796 |
| CombiganBrimonidine Tartrate/Timolol | 103 | $28,821 |
| RocklatanNetarsudil Mesylat/Latanoprost | 59 | $25,520 |
| Prednisolone Acetate | 335 | $13,154 |
| VyzultaLatanoprostene Bunod | 43 | $12,774 |
| RhopressaNetarsudil Mesylate | 27 | $12,274 |
| ZirganGanciclovir | 25 | $11,476 |
| Cyclosporine | 11 | $11,369 |
| Fluorometholone | 140 | $9,186 |
| Alphagan PBrimonidine Tartrate | 15 | $7,660 |
| Travatan ZTravoprost | 26 | $6,873 |
| Travoprost | 57 | $5,767 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $103 | $748,78021 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,223 | $205,920430 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Zirgan | $111 | $57,04593 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $373 | $37,79486 claims |
| NovartisTravatan Z | $435 | $6,87326 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $207 | $3,96721 claims |
| AlconSimbrinza | $715 | $3,27016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 712 optometrist providers in Kentucky.
Other optometrist in Louisville
- Lee PeplinskiLouisville$74K
- Austin LifferthLouisville$72K
- Aaron McNultyLouisville$22K
- Ian McWherterLouisville$18K
- Kevin SnipesLouisville$13K
- Richard ManganLouisville$12K
- Keith SlaydenLouisville$9K
- Benjamin PaxtonLouisville$8K
- Nikolaos ZagorianosLouisville$8K
- Fiona BoakLouisville$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.